Current Hematologic Malignancy Reports

, Volume 1, Issue 1, pp 51–59

First-line treatment of Hodgkin’s lymphoma


DOI: 10.1007/s11899-006-0018-3

Cite this article as:
Klimm, B., Engert, A. & Diehl, V. Curr Hematol Malig Rep (2006) 1: 51. doi:10.1007/s11899-006-0018-3


Substantial clinical progress over the last decades has made Hodgkin’s lymphoma into one of the most curable human cancers in adults. About 80% of patients in all stages and of all histologic subtypes experience long-term disease-free survival. Modern treatment strategies aim to improve chemotherapy and radiotherapy, while minimizing therapy-related toxicities. Ongoing trials investigate a reduction of chemotherapy doses or cycles and the application of lower radiation doses and smaller radiation field sizes. For patients with a specific high-risk profile, novel approaches with more intense drug combinations are currently being investigated in clinical trials. This review discusses recent approaches to the first-line treatment of early-favorable, early-unfavorable, and advanced-stage Hodgkin’s lymphoma.

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.First Department of Internal MedicineUniversity Hospital CologneCologneGermany